Walvax Biotechnology Co Ltd (300142):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Walvax Biotechnology Co Ltd (300142) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8224
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Walvax Biotechnology Co Ltd (Walvax) is a biopharmaceutical company that develops, produces and markets bio-medical products including vaccines and blood products. The company’s products include haemophilus influenzae vaccine for the prevention of infectious diseases such as meningitis. Walvax offers drugs for pneumonia, septicemia, cellulitis, arthritis and epiglottitis. It offers Group A, C meningococcal polysaccharide vaccine for preventing diseases such as cerebrospinal meningitis and septicemia; and Group ACYW135 meningococcal polysaccharide vaccine to prevent meningococcal disease. The company markets its products through a distribution network in China. The company operates a research and development center in Kunming. Walvax is headquartered in Kunming, China.

Walvax Biotechnology Co Ltd (300142) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
MabSpace Biosciences Enters into Agreement with Genor Biopharma 11
Licensing Agreements 12
Genor Biopharm Enters into Licensing Agreement with NewBio Therapeutics 12
Genor BioPharma Enters Into Licensing Agreement With BioCND For Biosimilars 13
RuiYi Enters Into Licensing Agreement With Genor BioPharma For RYI-008 14
Equity Offering 15
Walvax Biotech Raises USD89 Million in Private Placement of Shares 15
Genor BioPharma Raises USD81.8 Million in Private Placement 16
Walvax Biotech Raises USD72.9 Million in Private Placement of Shares 17
Debt Offering 18
Walvax Biotechnology Announces Public Offering Of Notes For US$188 Million 18
Walvax Biotechnology Plans Debt Offering For US$398 Million 19
Walvax Biotechnology Announces Public Offering Of Bonds For US$158 Million 20
Acquisition 21
Walvax Biotech Plans to Sell Stake in Shanghai-based Pharma-Tech for USD15.4 Million 21
Tianjin-based Limited Partnership Plans to Acquire 11.3% Stake in Walvax Biotechnology 22
Walvax Biotech to Sell 85% Stake in Shandong Shijie Biological Technology for USD104.5 Million 23
Walvax Biotech to Divest Kerry and Bio-Pharma and Heyzer Run Biotech for USD82 Million 24
Walvax Biotech to Sell 46% Stake in Hebei Da’an Pharma for USD103 Million 25
Walvax Biotech Plans to Acquire 51% Stake in Chongqing times Ning for USD29 Million 26
Walvax Biotech Receives Approval to Acquire Chongqing Beining Biological Pharma for USD57 Million 27
Walvax Biotechnology Acquires 63.57% Stake In Genor BioPharma From Shihezi Ansheng Investment And Wison Group for USD47.5 Million 28
Walvax Biotech Acquires Three Biomedical Companies 30
Walvax Biotechnology To Acquire Ningbo Biological Medicine Company For US$48.5 Million 31
Walvax Biotechnology To Acquire Putian Pharma Company For US$26.3 Million 32
Walvax Biotechnology To Acquire Shandong Biological Medicine Company For US$48.5 Million 33
Walvax Biotechnology Acquires 40.61% Stake In Shanghai Biotech Company For US$19.7 Million 34
Walvax Biotechnology To Acquire Additional 35% Stake In Hebei Da’an Pharma For US$54.6 Million 35
Yunnan Walvax Acquires 58% Stake In Shanghai Zerun Biotech For US$49 Million 36
Walvax Biotechnology Completes Acquisition Of 55% Stake In Hebei Da’an Pharma For Up To US$84 Million 37
Walvax Biotechnology Co Ltd – Key Competitors 38
Walvax Biotechnology Co Ltd – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Walvax Biotechnology Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MabSpace Biosciences Enters into Agreement with Genor Biopharma 11
Genor Biopharm Enters into Licensing Agreement with NewBio Therapeutics 12
Genor BioPharma Enters Into Licensing Agreement With BioCND For Biosimilars 13
RuiYi Enters Into Licensing Agreement With Genor BioPharma For RYI-008 14
Walvax Biotech Raises USD89 Million in Private Placement of Shares 15
Genor BioPharma Raises USD81.8 Million in Private Placement 16
Walvax Biotech Raises USD72.9 Million in Private Placement of Shares 17
Walvax Biotechnology Announces Public Offering Of Notes For US$188 Million 18
Walvax Biotechnology Plans Debt Offering For US$398 Million 19
Walvax Biotechnology Announces Public Offering Of Bonds For US$158 Million 20
Walvax Biotech Plans to Sell Stake in Shanghai-based Pharma-Tech for USD15.4 Million 21
Tianjin-based Limited Partnership Plans to Acquire 11.3% Stake in Walvax Biotechnology 22
Walvax Biotech to Sell 85% Stake in Shandong Shijie Biological Technology for USD104.5 Million 23
Walvax Biotech to Divest Kerry and Bio-Pharma and Heyzer Run Biotech for USD82 Million 24
Walvax Biotech to Sell 46% Stake in Hebei Da'an Pharma for USD103 Million 25
Walvax Biotech Plans to Acquire 51% Stake in Chongqing times Ning for USD29 Million 26
Walvax Biotech Receives Approval to Acquire Chongqing Beining Biological Pharma for USD57 Million 27
Walvax Biotechnology Acquires 63.57% Stake In Genor BioPharma From Shihezi Ansheng Investment And Wison Group for USD47.5 Million 28
Walvax Biotech Acquires Three Biomedical Companies 30
Walvax Biotechnology To Acquire Ningbo Biological Medicine Company For US$48.5 Million 31
Walvax Biotechnology To Acquire Putian Pharma Company For US$26.3 Million 32
Walvax Biotechnology To Acquire Shandong Biological Medicine Company For US$48.5 Million 33
Walvax Biotechnology Acquires 40.61% Stake In Shanghai Biotech Company For US$19.7 Million 34
Walvax Biotechnology To Acquire Additional 35% Stake In Hebei Da'an Pharma For US$54.6 Million 35
Yunnan Walvax Acquires 58% Stake In Shanghai Zerun Biotech For US$49 Million 36
Walvax Biotechnology Completes Acquisition Of 55% Stake In Hebei Da'an Pharma For Up To US$84 Million 37
Walvax Biotechnology Co Ltd, Key Competitors 38
Walvax Biotechnology Co Ltd, Subsidiaries 39

List of Figures
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Walvax Biotechnology Co Ltd (300142):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kuwait Food Company (Americana) K.S.C.P. (FOOD):企業の財務・戦略的SWOT分析
    Kuwait Food Company (Americana) K.S.C.P. (FOOD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Kezar Life Sciences Inc (KZR):製薬・医療:M&Aディール及び事業提携情報
    Summary Kezar Life Sciences Inc (Kezar Life Sciences) is a clinical-stage biotechnology company that discovers and develops small molecule therapies to treat autoimmunity and cancer. The company’s lead product candidate, KZR-616, an immunoproteasome inhibitor intended for the treatment of various au …
  • GlaxoSmithKline Plc (GSK)-医療機器分野:企業M&A・提携分析
    Summary GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respira …
  • Compugen Ltd (CGEN):企業の財務・戦略的SWOT分析
    Summary Compugen Ltd (Compugen) is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises COM701 and PVRIG; BAY 1905254, COM902 and TIGIT; and autoimmune diseases pipeline includes CGEN …
  • Triple Energy Ltd (TNP):石油・ガス:M&Aディール及び事業提携情報
    Summary Triple Energy Ltd (Triple Energy) is an oil and gas company that explores for natural resources. The company invests in oil and gas projects in the conventional and unconventional sectors such as coal seam gas and shale oil and gas, along with power generation. It offers project such as CFT …
  • Havells India Ltd (HAVELLS)-エネルギー分野:企業M&A・提携分析
    Summary Havells India Limited (Havells) is a fast moving electrical goods (FMEG) company that carries out the design, production and distribution of a range of world class industrial and consumer electrical products. Its products include building circuit protection products, capacitors, cables and w …
  • Suzano SA (SUZB5):企業の財務・戦略的SWOT分析
    Suzano SA (SUZB5) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Westar Energy Inc:発電所・企業SWOT分析
    Westar Energy Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Sempra Energy (SRE):石油・ガス:M&Aディール及び事業提携情報
    Summary Sempra Energy (Sempra) is an energy-services holding company. Through its subsidiaries, the company invests in, develops, and operates energy infrastructure. It carries out utility operations, development of energy infrastructure and related services in countries including the US, Mexico, Ar …
  • Regulus Therapeutics Inc (RGLS)-医療機器分野:企業M&A・提携分析
    Summary Regulus Therapeutics Inc (Regulus Therapeutics) is a developer of microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target microRNAs. Its products are used for the ther …
  • Transgene Biotek Ltd (526139):企業の財務・戦略的SWOT分析
    Summary Transgene Biotek Ltd (Transgene) is a biotechnology company that develops and commercializes bio-generic drugs and vaccines to treat autoimmune diseases and cancer. The company’s product portfolio includes TrabiDHA, a vegetarian source of DHA (Docosahexaenoic acid), used to manufacture healt …
  • Michelin SCA (ML):企業の財務・戦略的SWOT分析
    Michelin SCA (ML) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • American Overseas Group Limited:企業の戦略・SWOT・財務分析
    American Overseas Group Limited - Strategy, SWOT and Corporate Finance Report Summary American Overseas Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Adani Enterprises Ltd (ADANIENT):石油・ガス:M&Aディール及び事業提携情報
    Summary Adani Enterprises Ltd (Adani) is a diversified company with operations in resources, logistics and energy. It has interests in various businesses such as coal trading and mining, bunkering, renewable power generation, defense and aerospace, ports and special economic zones (SEZ), logistics, …
  • IBIDEN CO., LTD.:戦略・SWOT・企業財務分析
    IBIDEN CO., LTD. - Strategy, SWOT and Corporate Finance Report Summary IBIDEN CO., LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • CWC Energy Services Corp (CWC):企業の財務・戦略的SWOT分析
    Summary CWC Energy Services Corp (CWC) formerly CWC Well Services Corp, is an oilfield servicing company that provides drilling rigs, service rigs, coil tubing and well testing services in the Western Canadian Sedimentary Basin. The company operates through two divisions such as contract drilling an …
  • Nanjing Pharmaceutical Co Ltd (600713):企業の財務・戦略的SWOT分析
    Nanjing Pharmaceutical Co Ltd (600713) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • TPG Telecom Ltd (TPM):企業の財務・戦略的SWOT分析
    TPG Telecom Ltd (TPM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Malayan Flour Mills Berhad:戦略・SWOT・企業財務分析
    Malayan Flour Mills Berhad - Strategy, SWOT and Corporate Finance Report Summary Malayan Flour Mills Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Legg Mason Inc:企業の戦略・SWOT・財務情報
    Legg Mason Inc - Strategy, SWOT and Corporate Finance Report Summary Legg Mason Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆